Novel inhibitor of hematopoietic cell kinase as a potential therapeutic agent for acute myeloid leukemia (2022)
- Authors:
- Autor USP: REGO, EDUARDO MAGALHÃES - FM
- Unidade: FM
- DOI: 10.1007/s00262-021-03111-2
- Subjects: LEUCEMIA MIELOIDE; CÉLULAS-TRONCO; INIBIDORES DE ENZIMAS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Cancer immunology immunotherapy
- ISSN: 0340-7004
- Volume/Número/Paginação/Ano: v. 71, n. 8, p. 1909-1921, 2022
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: green
-
ABNT
ROVERSI, Fernanda Marconi et al. Novel inhibitor of hematopoietic cell kinase as a potential therapeutic agent for acute myeloid leukemia. Cancer immunology immunotherapy, v. 71, n. 8, p. 1909-1921, 2022Tradução . . Disponível em: https://doi.org/10.1007/s00262-021-03111-2. Acesso em: 29 set. 2024. -
APA
Roversi, F. M., Bueno, M. L. P., Silva, J. A. F. da, Assis-Mendonca, G. R., Torello, C. O., Shiraishi, R. N., et al. (2022). Novel inhibitor of hematopoietic cell kinase as a potential therapeutic agent for acute myeloid leukemia. Cancer immunology immunotherapy, 71( 8), 1909-1921. doi:10.1007/s00262-021-03111-2 -
NLM
Roversi FM, Bueno MLP, Silva JAF da, Assis-Mendonca GR, Torello CO, Shiraishi RN, Pericole FV, Ferro KP, Duarte ASS, Rego EM, Saad STO. Novel inhibitor of hematopoietic cell kinase as a potential therapeutic agent for acute myeloid leukemia [Internet]. Cancer immunology immunotherapy. 2022 ; 71( 8): 1909-1921.[citado 2024 set. 29 ] Available from: https://doi.org/10.1007/s00262-021-03111-2 -
Vancouver
Roversi FM, Bueno MLP, Silva JAF da, Assis-Mendonca GR, Torello CO, Shiraishi RN, Pericole FV, Ferro KP, Duarte ASS, Rego EM, Saad STO. Novel inhibitor of hematopoietic cell kinase as a potential therapeutic agent for acute myeloid leukemia [Internet]. Cancer immunology immunotherapy. 2022 ; 71( 8): 1909-1921.[citado 2024 set. 29 ] Available from: https://doi.org/10.1007/s00262-021-03111-2 - Trangenic mice expressing hCG-NuMA-RAR'alfa' develop hematopoietic abnormalities leading to acute promyelocytic leukemia
- Role od promyelocytic leukemia (PML) protein in tumor suppression
- Estudo da relevância da inativação do CCAAT enhancer binding protein 'alfa' (C/EBP'alfa') na gênese da leucemia promielocítica
- Linfomas não Hodgkin de células T maduras e de células NK extramodais
- Identification of myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia
- Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma
- Association between the TP53 Arg72Pro polymorphism and clinical outcomes in acute myeloid leukemia
- Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk
- Anemia e palidez
- Temporal trends in Hematopoietic Stem Cell Transplantation in Argentina. [Editorial]: regional differences that mirror the global reality
Informações sobre o DOI: 10.1007/s00262-021-03111-2 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
